Hirokazu Nagai, MD, PhD

Center/Department

Clinical Research Center
Director, Clinical Research Center
Director, Department of Clinical Research Management
Director, Department of Hematology and Oncology Research
Chief, Division of Administration

 

Interest

clinical hematology, clinical oncology, (chemotherapy, stem cell transplantation) molecular biology

 

Area of Research

Clinical and molecular hemato-oncology

 

Contact Information

Hirokazu Nagai, MD, PhD
Laboratory of Adbanced Therapy
Department of Hematology and Oncology Research
Clinical Research Center
National Hospital Organization Nagoya Medical Center
4-1-1 Sannomaru, Naka-ku, Nagoya
Aichi 460-0001, Japan
Tel: +81-52-951-1111
Fax: +81-52-951-0664
Email: hirokazu.nagai[at]nnh.go.jp
Preferred contact method: e-mail

 

Research

Development of new therapeutic strategy against malignant lymphoma including AIDS-related lymphoma.
Molecular diagnmosis of minimal residual diseases of malignant lymphoma

 

Biography

M.D. Kanazawa University, School of Medicine, 1985
Ph.D. Nagoya University, School of Medicine, 1993

1985  graduated from Kanzawa University, School of Medicine
1985-1988  Nagoya National Hospital (clinical resident)
1988-1989  Toyohashi National Hospital (clinical staff)
1989-1990  Tokyo Metropolitan Komagome Hospital (clinical staff)
1990-1992  National Cancer Center, Research Institute (research resident)
1992-1993  Nagoya University Hospital (clinical staff)
1993-1995  Jefferson Cancer Institute (USA) (postdoctoral fellow)
1995-2001  Nagoya University Hospital (clinical staff)
2001-present  Nagoya Medical Center (clinical staff)
2002-present  Nagoya Medical Center (director of department of hematology/oncology research)

 

Selected Publications

Nagai H, et al.
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma
Eur J Haematol. 86:117-123, 2011

Nagai H, et al
Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.
Eur J Haematol. 84:499-505, 2010

Hagiwara K, Nagai H. et al.
Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma
Leukemia Res. 34: 50-54, 2010

Terasawa T and Nagai H
Current clinical evidence on interim FDG-PET for advanced-stage Hodgkin’s lymphomaand diffuse large B-cell lymphoma to predict treatment outcomes
Leukemia Lymphoma. 50; 1750-1754, 2009

Terasawa T, Nagai H et al.
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin’s Lymphoma and DiffuseLarge B-cell Lymphoma: A Systematic Review
J Clin Oncol. 27; 1906-1914, 2009

Nagai H. et al.
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma
British J Haematol. 143: 672-680, 2008

Nagai H et al.
Actual status of AIDS-related lymphoma management in Japan.
Int J Hematol. 87: 442-443, 2008

Terazawa T, Nagai H. et al.
Fluorine-18-fluorodeoxyglucose positron emission tomography for post-therapy assessment of Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphpoma.
J Nucl Med 49: 13-21, 2008